Securities code: 300138 securities abbreviation: Chenguang Biotech Group Co.Ltd(300138) Announcement No.: 2022-011 Chenguang Biotech Group Co.Ltd(300138)
Announcement of resolutions of the 38th meeting of the 4th board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
The board of directors of Chenguang Biotech Group Co.Ltd(300138) (hereinafter referred to as “the company”) sent the notice of the 38th meeting of the Fourth Board of directors to all directors by personal delivery and e-mail on February 14, 2022, and the meeting was held in the company’s conference room on February 19, 2022 in the combination of on-site and communication. The meeting was presided over by Mr. Lu Qingguo, chairman of the board of directors. There were six directors who should attend the meeting and six directors who actually attended the meeting (director Li yuezhai, independent directors Liu Zhanglin, Zhou Fangsheng and Wang Shuhong participated by means of communication). The supervisors of the company attended the meeting as nonvoting delegates. The meeting was held in accordance with the company law, the articles of association and other relevant regulations. After study and discussion by the directors present at the meeting, the following proposals were considered and adopted:
1、 The proposal on using some idle raised funds to temporarily supplement working capital was deliberated and adopted. In order to improve the use efficiency of raised funds, on the premise of ensuring the capital demand of investment projects with raised funds, according to the Listing Rules of gem shares of Shenzhen Stock Exchange No. 2 self regulatory guidelines for listed companies of Shenzhen Stock Exchange – standardized operation of GEM listed companies, articles of association and other relevant requirements, combined with the company’s business needs and financial situation, The company plans to use the temporarily idle raised funds of no more than 325 million yuan of “integrated natural plant extraction project (phase I)” to temporarily supplement the working capital required for daily operation. The period shall not exceed 12 months from the date of deliberation and approval of this proposal by the board of directors, and will be returned to the special account for raised funds before expiration. The independent directors, the board of supervisors and the recommendation institution of the company respectively expressed their consent on this matter. For details, please refer to the announcement documents disclosed on cninfo.com in the same period.
Voting result: Six affirmative votes; No votes; No abstentions.
It is hereby announced
Chenguang Biotech Group Co.Ltd(300138) board of directors
February 21, 2022
